Establishment Labs Holdings Inc (NASDAQ:ESTA) Major Shareholder Purchases $37,965.00 in Stock

Establishment Labs Holdings Inc (NASDAQ:ESTA) major shareholder Jw Asset Management, Llc purchased 1,500 shares of the stock in a transaction on Wednesday, July 31st. The shares were purchased at an average cost of $25.31 per share, with a total value of $37,965.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Jw Asset Management, Llc also recently made the following trade(s):

  • On Monday, July 29th, Jw Asset Management, Llc acquired 2,500 shares of Establishment Labs stock. The stock was bought at an average cost of $25.58 per share, with a total value of $63,950.00.

Shares of ESTA stock opened at $24.60 on Monday. The company has a 50-day moving average of $22.67. The company has a quick ratio of 4.10, a current ratio of 5.54 and a debt-to-equity ratio of 0.38. Establishment Labs Holdings Inc has a 52-week low of $20.05 and a 52-week high of $30.70.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.13). The company had revenue of $20.78 million during the quarter, compared to analyst estimates of $18.50 million. Establishment Labs had a negative net margin of 37.74% and a negative return on equity of 68.22%. As a group, equities research analysts expect that Establishment Labs Holdings Inc will post -1.94 earnings per share for the current fiscal year.

Several equities analysts have recently issued reports on ESTA shares. Stephens started coverage on Establishment Labs in a report on Thursday, June 6th. They issued an “overweight” rating and a $37.00 price objective for the company. BTIG Research reissued a “buy” rating and issued a $40.00 price objective on shares of Establishment Labs in a report on Thursday, May 16th. ValuEngine raised Establishment Labs from a “hold” rating to a “buy” rating in a report on Monday, July 29th. Finally, Wells Fargo & Co set a $29.00 price objective on Establishment Labs and gave the company a “buy” rating in a report on Friday, July 12th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $35.20.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue.

Featured Story: Are 12b-1 Fees Affecting Your Mutual Fund Performance?

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with's FREE daily email newsletter.